Radiotherapy Combination: Insight From Tumor Immune Microenvironment (Time) Publisher



Alimohammadi M¹ ; Ghaffarinazari H² ; Alimohammadi R³ ; Bakhshandeh M⁴ ; Jalali SA³ ; Rezaei N¹ Show Affiliations
Source: Avicenna Journal of Medical Biotechnology Published:2023

Abstract

The view of Radiotherapy (RT) as a simple inducer of DNA damage resulting in tumor cell death has dramatically changed in recent years, and it is now widely accepted that RT can trigger an immune response which provides a sound basis for combining RT with immunotherapy. Given that, radiation can be delivered with different regimens, its effect on immune responses and Tumor Immune Microenvironment (TIME) may vary with dose and fractionation schedule. This fractional dose dependency may need to be more considered because of recent developments in RT delivery techniques making it possible to deliver precisely higher dosages per fraction (hypofractionation) while reducing exposure to normal tissues. Although combining radiotherapy with immunotherapy could be a promising strategy for synergistic enhancement of treatment efficacy, the selection of the best-matched combination of immunotherapy with each radiotherapy scheme remains to be addressed. Thus, for designing better therapeutic combinations, it is necessary to understand the immunological effects of RT. Here, we review the impact of conventional and different hypofractionation radiation schedules on the TIME. Sub-sequently, we highlight how knowing about these interactions may have implications for choosing a rational combination with targeted therapies. © 2023, Avicenna Journal of Medical Biotechnology. All rights reserved.